Although c-Jun NH 2 -terminal kinase (JNK) is activated by treatment with therapeutic agents, the biologic sequelae of inhibiting constitutive activation of JNK has not yet been clarified. In this study, we examine the biologic effect of JNK inhibition in multiple myeloma (MM) cell lines. JNK-specific inhibitor SP600125 induces growth inhibition via induction of G1 or G2/M arrest in U266 and MM.1S multiple myeloma cell lines, respectively. Neither exogenous IL-6 nor insulin-like growth factor-1 (IGF-1) overcome SP600125-induced growth inhibition, and IL-6 enhances SP600125-induced G2/M phase in MM.1S cells. Induction of growth arrest is mediated by upregulation of p27 Kip1 , without alteration of p53 and JNK protein expression. Importantly, SP600125 inhibits growth of MM cells adherent to bone marrow stromal cells (BMSCs). SP600125 induces NF-jB activation in a dose-dependent fashion, associated with phosphorylation of IjB kinase a (IKKa) and degradation of IjBa. In contrast, SP600125 does not affect phosphorylation of STAT3, Akt, and/or ERK. IKK-specific inhibitor PS-1145 inhibits SP600125-induced NF-jB activation and blocks the protective effect of SP600125 against apoptosis. Our data therefore demonstrate for the first time that inhibiting JNK activity induces growth arrest and activates NF-jB in MM cells.
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It has been demonstrated that JNK also modulates cell cycle and transcriptional responses to stress (Pearce and Humphrey, 2001) . For example, depletion of JNK1 or JNK2 suppresses growth and inhibits DNA synthesis of cells cultured in nonstress conditions. Additionally, JNK2-antisense oligonucleotide induces p21
Cip1 via a p53-independent pathway in glioblastoma cells (Potapova et al., 2000) . c-Jun is a downstream substrate of JNK, and c-Jun-deficient murine embryo fibroblasts exhibit a senescence-like growth arrest (Schreiber et al., 1999) ; c-Jun may therefore mediate JNK-associated cell cycle regulation. However, to date, the biologic sequelae of inhibiting constitutive JNK activation in MM cells is unknown. To address this question, we used the JNKspecific inhibitor SP600125 (Calbiochem, San Diego, CA, USA), which inhibits phosphorylation of JNK1/2 and their downstream targets c-Jun and ATF-2 (Hideshima et al., 2003b) and inhibits PS-341-induced or stress-induced apoptosis (Chauhan et al., 2003) (Figure 1a ). To confirm these effects of SP600125 on these cell lines, we next assessed constitutive activation of JNK using an in vitro pull-down JNK kinase assay. JNK is constitutively activated in both MM.1S and U266 MM cell lines, and SP600125 inhibits JNK kinase activity in a dose-dependent fashion (Figure 1b) .
The dissociation of the results of MTT assay versus [ 3 H]thymidine uptake suggests that SP600126 induces MM cell growth arrest, and we therefore next examined the cell cycle profile analysis in MM.1S and U266 cells before and after SP600125 treatment. As expected, cell cycle profile analysis demonstrated that SP600125 induces G1 and G2/M phase arrest in U266 and MM.1S cells, respectively ( Figure 1c ). In studies to define the mechanisms underlying growth arrest triggered by SP600125, we found that p21
Cip1 was significantly upregulated in a time-dependent fashion , and the cell lines were maintained as previously described (Hideshima et al., 2000) . (a) The inhibitory effect of SP600125 (2.5-20 mm) on MM.1S, MM.1R, U266, RPMI8226, and RPMI-Dox40 MM cell line growth was assessed by measuring 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide (MTT, Chemicon International Inc., Temecula, CA, USA) dye absorbance and [ in MM.1S and U266 cells after treatment, whereas upregulation of p27
Kip1 was recognized only in MM.1S cells (Figure 1d ), suggesting that p21
Cip1 may mediate growth arrest. In contrast, neither p53 nor JNK1 expression was altered by SP600125. Since we have shown that MM.1S and U266 have wild-type-and mutant p53, respectively (Hideshima et al., 2000) , these data suggest that upregulation of p21 Cip1 is p53 independent. The mechanisms modulating expression of these proteins are under investigation.
We and others have shown that both IL-6 (Klein et al., 1995; Lichtenstein et al., 1995; Chauhan et al., 1997; Ogata et al., 1997; Tu et al., 2000; Hideshima et al., 2001b) and IGF-1 (Freund et al., 1993; Mitsiades et al., 2002a, b) mediate growth and antiapoptosis in MM cells. We next examined whether IL-6 or IGF-1 overcomes SP600125-induced MM cell growth inhibition. Importantly, neither IL-6 nor IGF-1 abrogates the effect of SP600125 in both MM.1S and U266 cells (Figure 2a ). Interestingly, cell cycle profile analysis demonstrates that treatment of MM.1S cells with SP600125 plus IL-6 induces increased G2/M phase cells compared to SP600125 alone, due to triggering of DNA synthesis by IL-6 (Figure 2b) . Neither IL-6 nor IGF-1 alters p21
Cip1 or p27 Kip1 expression in SP6001525-treated MM.1S cells (data not shown).
Given the result that neither IL-6 nor IGF-1 overcomes the growth inhibitory effect of SP600125, we next further examined the effect of SP600125 in the BM microenvironment. Specifically, we have shown that the BM microenvironment promotes MM cell growth and drug resistance (Hideshima et al., 2001a , and we next therefore studied whether SP600125 inhibits growth of MM cells in the BM milieu. MM.1S and U266 cells were cultured with or without BMSCs, in the presence or absence of SP600125. SP600125, in a dose-dependent fashion, inhibits the increased [ We and others have shown that extracellular signalregulated kinase (ERK) , Akt (Tu et al., 2000; Hideshima et al., 2001b; Mitsiades et al., 2002b) , signal transducers and activators of transcription 3 (STAT3), and NF-kB Mitsiades et al., 2002b) signaling mediates MM cell proliferation and survival. Specifically, NF-kB plays an important role in MM by modulating IL-6 transcription and secretion from BMSCs (Chauhan et al., 1996) , as well as regulating antiapoptotic protein expression in MM (Mitsiades et al., 2002c) . We next, therefore, further examined the effect of SP600125 on these signaling pathways in MM.1S and U266 cells. Although SP600125 moderately increases constitutive phosphorylation of ERK in MM.1S cells, it does not inhibit constitutive phosphorylation of STAT3 or Akt in MM.1S and/or U266 cells (Figure 4a) . Surprisingly, SP600125 activates NF-kB in both MM.1S and U266 cells in a dose-dependent fashion (Figure 4b ). SP600126 also phosphorylates p65 NF-kB in both MM.1S and U266 cells (Figure 4c) . Importantly, SP600125 induces phosphorylation of IKKa, followed by degradation of IkBa (Figure 4c ). Consistent with SP600125-induced IKKa phosphorylation, the IKK inhibitor PS-1145 decreases SP600125-induced NF-kB activation in MM.1S cells (Figure 4c ). These results suggest that NF-kB activation triggered by SP600125 is mediated via interaction of JNK with IKK or upstream molecules in the NF-kB signaling cascade, and that JNK may play a role in inhibiting constitutive activation of NF-kB in MM cells, without altering ERK, STAT3, or Akt activation. Given that SP600125 induces NF-kB Whole-cell lysates were subjected to Western blotting to assess phosphorylation and protein expression of STAT3, Akt, and ERK using specific Abs against these proteins (Cell Signaling, Beverly, MA, USA). (b) NF-kB activity before and after SP600125 treatment of MM cells was assessed by electrophoretic mobility shift analyses (EMSA) using nuclear extracts and 32 P-labeled NFkB binding consensus oligonucleotide probe (5 0 -GGGGACT TTCCC-3 0 , Santa Cruz Biotech.), as in our previous studies (Hideshima et al., 2001a (Hideshima et al., , c, 2002 . Both MM.1S and U266 cells were cultured with SP600125 (5-20 mm) for 24 h. Nuclear extracts were subjected to EMSA. (c) MM.1S and/or U266 cells were cultured with DMSO control media, and with 5 mm, 10 mm, and/or 20 mm SP600125 for 24 h. Whole-cell lysates were subjected to Western blotting to assess phosphorylation and protein expression of p65 NF-kB, IKK, and IkBa (Cell Signaling, Beverly, MA, USA). a-tubulin (Sigma) served as a control for equal protein loading. (d) MM.1S cells were cultured with 10 mm SP600125 for 24 h, in the presence or absence of 10 mm PS-1145 (Millennium Pharmaceuticals, Cambridge, MA, USA) . Nuclear extracts were subjected to EMSA. (Hideshima et al., 2003a )-induced apoptosis is mediated via activation of NF-kB. As expected, PS-1145 blocks the protective effect of SP600125 against apoptosis in MM.1S cells (Figure 4d ), consistent with our previous studies demonstrating that both PS-341-and 2ME-2-induced apoptosis is inhibited by SP600125 (Chauhan et al., 2003; Hideshima et al., 2003b) . Many apoptotic stimuli activate JNK during induction of apoptosis (Herr et al., 1999; Chen and Lai, 2001) , and overexpression of JNK augments taxol-induced cytotoxicity in breast cancer. On the other hand, we have shown that proteasome inhibitor PS-341 induces JNK activation and that SP600125 inhibits PS-341-induced apoptosis (Hideshima et al., 2003b) . Taken together, our studies suggest that the antiapoptotic effect by SP600125 in MM cells is mediated, at least in part, via activation of NF-kB; our ongoing studies are delineating the molecular mechanisms whereby JNK inhibitor induces NF-kB activation in MM cells. In conclusion, our results suggest for the first time that constitutive activation of JNK regulates cell cycle and inhibits NFkB activation in MM cells.
